The impact of DAA-mediated HCV eradication on CD4
CD4
CD8
DAA
HCV/HIV
immune activation
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
27
12
2020
accepted:
31
01
2021
pubmed:
19
2
2021
medline:
2
10
2021
entrez:
18
2
2021
Statut:
ppublish
Résumé
HCV infection has been hypothesized as a contributor of poor CD4
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
779-786Investigateurs
M Andreoni
(M)
A Castagna
(A)
F Castelli
(F)
R Cauda
(R)
G Di Perri
(G)
M Galli
(M)
R Iardino
(R)
G Ippolito
(G)
A Lazzarin
(A)
G C Marchetti
(GC)
G Rezza
(G)
F von Shloesser
(F)
P Viale
(P)
A Castagna
(A)
E Girardi
(E)
S Lo Caputo
(S)
F Maggiolo
(F)
C F Perno
(CF)
F Bai
(F)
S Bonora
(S)
M Borderi
(M)
A Calcagno
(A)
M R Capobianchi
(MR)
A Castagna
(A)
S Cicalini
(S)
A Cingolani
(A)
P Cinque
(P)
A Di Biagio
(A)
R Gagliardini
(R)
E Girardi
(E)
N Gianotti
(N)
G Guaraldi
(G)
M Lichtner
(M)
A Lai
(A)
G Madeddu
(G)
F Maggiolo
(F)
G Marchetti
(G)
E Merlini
(E)
S Nozza
(S)
C F Perno
(CF)
S Piconi
(S)
C Pinnetti
(C)
R Rossotti
(R)
S Rusconi
(S)
M M Santoro
(MM)
L Sarmati
(L)
V Spagnuolo
(V)
V Svicher
(V)
I Fanti
(I)
L Galli
(L)
A Rodano'
(A)
M Macchia
(M)
A Tavelli
(A)
A Bove
(A)
A Camposeragna
(A)
M Errico
(M)
M Manfredini
(M)
A Perziano
(A)
V Calvino
(V)
F Carletti
(F)
S Carrara
(S)
A Di Caro
(A)
S Graziano
(S)
F Petroni
(F)
G Prota
(G)
S Truffa
(S)
A Giacometti
(A)
A Costantini
(A)
V Barocci
(V)
G Angarano
(G)
L Monno
(L)
E Milano
(E)
F Maggiolo
(F)
C Suardi
(C)
P Viale
(P)
V Donati
(V)
G Verucchi
(G)
F Castelnuovo
(F)
C Minardi
(C)
B Menzaghi
(B)
C Abeli
(C)
L Chessa
(L)
F Pes
(F)
B Cacopardo
(B)
B Celesia
(B)
J Vecchiet
(J)
K Falasca
(K)
A Pan
(A)
S Lorenzotti
(S)
L Sighinolfi
(L)
D Segala
(D)
P Blanc
(P)
F Vichi
(F)
G Cassola
(G)
M Bassetti
(M)
A Alessandrini
(A)
N Bobbio
(N)
G Mazzarello
(G)
M Lichtner
(M)
L Fondaco
(L)
P Bonfanti
(P)
C Molteni
(C)
A Chiodera
(A)
P Milini
(P)
G Nunnari
(G)
G Pellicanò
(G)
M Galli
(M)
A Lazzarin
(A)
G Rizzardini
(G)
A Castagna
(A)
E S Cannizzo
(ES)
M C Moioli
(MC)
R Piolini
(R)
D Bernacchia
(D)
A Poli
(A)
C Tincati
(C)
C Puzzolante
(C)
C Migliorino
(C)
V Sangiovanni
(V)
G Borgia
(G)
V Esposito
(V)
G Di Flumeri
(G)
I Gentile
(I)
V Rizzo
(V)
A M Cattelan
(AM)
S Marinello
(S)
A Cascio
(A)
M Trizzino
(M)
D Francisci
(D)
E Schiaroli
(E)
G Parruti
(G)
F Sozio
(F)
C Lazzaretti
(C)
R Corsini
(R)
M Andreoni
(M)
R Cauda
(R)
A Cristaudo
(A)
V Vullo
(V)
R Acinapura
(R)
S Lamonica
(S)
M Capozzi
(M)
A Mondi
(A)
A Cingolani
(A)
M Rivano Capparuccia
(M)
G Iaiani
(G)
A Latini
(A)
G Onnelli
(G)
M M Plazzi
(MM)
G De Girolamo
(G)
A Vergori
(A)
M Cecchetto
(M)
F Viviani
(F)
G Madeddu
(G)
A De Vito
(A)
B Rossetti
(B)
A Franco
(A)
R Fontana Del Vecchio
(R)
C Di Giuli
(C)
P Caramello
(P)
G Di Perri
(G)
S Bonora
(S)
G C Orofino
(GC)
M Sciandra
(M)
A Londero
(A)
V Manfrin
(V)
G Battagin
(G)
G Starnini
(G)
A Ialungo
(A)
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. Curr Opin HIV AIDS. 2016;11(2):191-200.
Hodowanec AC, Lee RD, Brady KE, et al. A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection. BMC Infect Dis. 2015;15:190.
Márquez M, Romero-Cores P, Montes-Oca M, et al. Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection. PLoS One. 2015;10(3):e0119568.
Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol. 2009;83(21):11407-11411.
Sajadi MM, Pulijala R, Redfield RR, Talwani R. Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. AIDS. 2012;26(15):1879-1884.
Hodowanec AC, Brady KE, Gao W, et al. Characterization of CD4+ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2013;64(3):232-240.
Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013;254(1):78-101.
Gazzola L, Tincati C, Bellistrì GM, d’Arminio MA, Marchetti G. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis. 2009;48(3):328-337.
Kushner LE, Wendelboe AM, Lazzeroni LC, et al. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PLoS One. 2013;8(4):e60387.
Chew KW, Hua L, Bhattacharya D, et al. The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis. 2014;1(3):ofu104.
López-Cortés LF, Trujillo-Rodríguez M, Báez-Palomo A, et al. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018;218(4):624-632.
Emmanuel B, El-Kamary SS, Magder LS, et al. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients. Hepatol Int. 2019;13(3):270-276.
Shmagel KV, Korolevskaya LB, Saidakova EV, et al. HCV coinfection of the HIV-infected patients with discordant CD4+ T-cell response to antiretroviral therapy leads to intense systemic inflammation. Dokl Biol Sci. 2017;477(1):244-247.
Maria AD, Cossarizza A. CD4saurus Rex & HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution. J Transl Med. 2011;9:93.
Meissner EG, Kohli A, Higgins J, et al. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun. 2017;1(7):586-594.
Orr C, Aartun J, Masur H, Kottilil S, Meissner EG. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019;26(3):323-328.
Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999;30(3):376-382.
Powers CN, Peavy DL, Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob Agents Chemother. 1982;22(1):108-114.
EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153-194.
Martín J, Navas S, Quiroga JA, Pardo M, Carreño V. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine. 1998;10(8):635-644.